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ABSTRACT 
Drug-induced liver injury (DILI) is a major cause of post-marketing drug withdrawals and 
restricted-use warnings. In addition, unexpected adverse hepatic drug reactions occurring in 
the clinical phases of development are a major reason for drug attrition. Currently, there is an 
unmet need for reliable in vitro models to faithfully study the impact of drugs on the human 
liver. 
In this thesis, we developed and extensively characterized a novel three-dimensional (3D) 
spheroid culture system comprised of primary human hepatocytes (PHH). We found that the 
proteomes of PHH in 3D spheroid culture closely resemble those observed in the liver in 
vivo, whereas in conventional two-dimensional (2D) monolayer cultures PHH rapidly lose 
their mature phenotype due to dedifferentiation. 
PHH spheroids retain stable molecular phenotypes and liver-specific functionalities for 
multiple weeks in culture. These features allow prediction of DILI events, including those 
that may be delayed in onset, in a more phenotypically adequate system. Moreover, the PHH 
spheroid system was found suitable to detect the liability of drugs to induce cholestasis and to 
identify concomitant toxicity mechanisms. 
Our results also indicate that PHH spheroids can be used to screen drugs for cytochrome 
P450 3A4 (CYP3A4) induction. Importantly, PHH in 3D spheroid culture could identify a 
clinically relevant atypical mechanism of CYP3A4 induction that was not possible to detect 
in the corresponding 2D monolayer cultures. 
In conclusion, the PHH spheroid system presented here constitutes a versatile in vitro model 
to study liver biology and to assess the metabolic and toxicological profiles of drugs and drug 
candidates. 
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1 INTRODUCTION 
1.1 ADVERSE DRUG REACTIONS 
Novel drugs for prevention, treatment, or cure of diseases are constantly being developed, 
optimized, and tailored to patient-specific needs. Undoubtedly in the vast majority of cases 
the benefits of drug therapy outweigh the associated side effects and risks. Nevertheless, the 
occurrence of adverse drug reactions (ADRs) remains a significant problem in clinical 
practice, in part due to the increased complexity of therapeutic regimes associated with the 
rise in global multimorbidity (1). ADRs are suspected to directly cause or contribute to  
5-18% of all in-hospital deaths (2-4) and are ranked as the seventh most common cause of 
death in the general population of Sweden (5). Approximately 5% of all hospital admissions 
are associated with ADRs and it is estimated that 5-10% of all hospitalized patients 
experience an ADR (6-11). As such, a significant economic burden is placed on healthcare 
systems, with reported annual costs of 30.1 billion USD in the United States due to increased 
hospitalization rates and prolonged hospital stays (12). The incidence and burden of ADRs 
may however significantly exceed the reported numbers since ADRs are notoriously under-
reported, which is a major challenge in pharmacovigilance worldwide (13-16). 
Bringing a new drug from concept to market is a highly protracted and costly process, taking 
on average 13-15 years with associated costs estimated at 1.3 billion USD (17, 18). Since the 
1990s, the performance of the pharmaceutical industry has been alarming, with low numbers 
of new drug approvals by the Food and Drug Administration (FDA) (19-23). However, 
AstraZeneca recently reported a marked improvement in their project success rates from 
candidate drug nomination to phase III completion from 4% in 2005-2010 to 19% in 2012-
2016 (24), suggesting productivity may be on the rise again. In addition, the FDA approved 
46 new drugs in 2017, the highest number since 1996 (25).  
Still, a major challenge the pharmaceutical industry currently faces is to address and reduce 
the high attrition rates in drug development. While in the early 1990s adverse 
pharmacokinetic and bioavailability profiles were the most common reason for attrition, the 
contribution of these factors has significantly decreased in recent years. Instead, lack of 
efficacy and safety issues are now two of the most frequent causes of attrition (22, 26, 27). 
Analysis of 605 compounds terminated from development between 2000 and 2010 revealed 
that non-clinical toxicology and clinical safety issues accounted for over 50% of all failures 
(27). In the same period, 32% of newly FDA-approved therapeutics were affected by post-
market safety events, including withdrawals, restricted-use warnings, and issuance of safety 
communications (28). Thus, unexpected ADRs are of major concern for public health and 
remain a key challenge for the pharmaceutical industry during both pre- and post-marketing 
stages of drug development. 
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1.2 DRUG-INDUCED LIVER INJURY 
1.2.1 Epidemiology  
Between 1953 and 2013, 462 medicinal products were withdrawn from the pharmaceutical 
market in one or more countries because of severe ADRs, including death which was 
documented as the reason for a quarter of these cases. Hepatotoxicity was reported as the 
most frequent reason for withdrawal, accounting for 18% of all cases (29). Indeed, drug-
induced liver injury (DILI) continues to be a major concern for public health, surpassing viral 
hepatitis as the most common cause of acute liver failure (ALF) in the United States (30). 
Almost 50% of ALF cases are due to intentional or accidental acetaminophen (APAP) 
overdose while approximately 11% are due to idiosyncratic drug reactions (31). The latter 
cause of ALF is often more severe and associated with poor outcome, having a mere 27% 
transplant-free survival rate (31, 32). Fortunately, the incidence of idiosyncratic DILI is rare, 
crudely estimated at ~19 cases per 100,000 individuals annually (33). However, this is likely 
an underestimation due to serious under-reporting because of the lack of surveillance systems 
and the concomitant challenges in its recognition and diagnosis (34). Despite its infrequency, 
the clinical outcomes can be severe. One in five patients will develop chronic liver injury and 
in nearly 10% of all cases it is, directly or indirectly, the cause of fatality or need for liver 
transplantation (35-37). 
1.2.2 Classification 
Conventionally, DILI has been classified into either having an underlying intrinsic or 
idiosyncratic mechanism of toxicity. DILI is referred to as intrinsic when the toxicity is 
clearly dose-dependent and occurs in a predictable and reproducible manner. On the other 
hand, idiosyncratic DILI is often delayed in onset and is the result of a complex interplay 
between drug properties, individual sensitivity factors, and environmental factors (38). Other 
than APAP, there are few drugs currently used in the clinic known to pose the risk of intrinsic 
liver injury, because this type of drug liability can normally be detected in drug development, 
resulting in either drug termination, changing the route of drug administration, or 
continuation of the drug but at doses well below the toxicity threshold (39). In recent years 
however, intrinsic and idiosyncratic DILI have thought to be coinciding rather than existing 
as two separate entities, where it is hypothesized that other factors such as inflammatory 
stress can sensitize certain individuals towards intrinsic hepatotoxins, ultimately resulting in 
idiosyncratic liver injury (40, 41). Evidence substantiating this hypothesis is provided by the 
finding that pharmacological doses of APAP in patients hospitalized for acute viral hepatitis 
can provoke serious liver injury (42). Further supporting this notion is the fact that in around 
10% of ALF cases linked to APAP toxicity occurs at the recommended dose (43, 44).  
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1.2.3 Clinical presentation 
Clinical symptoms of idiosyncratic DILI are often vague and nonspecific (e.g. lethargy, 
nausea, vomiting, and abdominal pain). In more serious cases liver-specific symptoms such 
as jaundice and encephalopathy may be present (45). Because of the diverse disease 
representation, idiosyncratic DILI can phenotypically mimic virtually all primary liver 
diseases, in particular acute viral hepatitis. As such, this inevitably leads to frequent 
misdiagnoses that can negatively impact on patient care (46). Currently, reliable and 
objective biomarkers of DILI are scarce, making it a diagnosis of exclusion based on 
reviewing the patient’s history to exclude competing etiologies and relying on blood tests, 
hepatobiliary imaging, and occasionally liver biopsies (47).  
Biochemically, the pattern of DILI can be subdivided into hepatocellular, cholestatic or a 
mixed pattern based on the ratio of elevation of baseline alanine aminotransferase (ALT) to 
baseline alkaline phosphatase (ALP) (48-50). In case of hepatocellular injury, ALT is 
markedly elevated while ALP elevations are modest. However, generally, the degree of ALT 
elevation poorly correlates with the severity of disease and often underestimates the degree of 
injury (51). Compared to other patterns of DILI, the hepatocellular type is more likely to 
progress to ALF (52). Cholestasis and mixed patterns are frequently observed in the clinic, 
accounting in some reports for up to half of all DILI cases (33, 53). While mortality rates are 
lower for cholestatic and mixed patterns of injury, normalization of liver function tests is 
protracted and the risk for chronic injury is higher (54). Other less commonly observed 
patterns of DILI include steatohepatitis, granulomatous hepatitis, neoplasms, and vascular 
abnormalities (55). 
An important feature that aids in making the diagnosis of DILI is recognition of specific 
patterns of liver injury and the concomitant latencies that are characteristic for certain drugs. 
Drug classes frequently associated with DILI include antimicrobials (in particular 
amoxicillin-clavulanate), cardiovascular agents, central nervous system agents, and 
antineoplastics (56). Moreover, reports of idiosyncratic liver injury from herbal products and 
dietary supplements have been on the rise in recent years (57). Ongoing efforts to more 
confidently and rapidly recognize DILI in the clinic are aimed at identification of novel DILI-
specific biomarkers by analyzing blood and tissue samples from idiosyncratic DILI cases. 
Emerging examples include microRNA-122, high mortality group box 1, and keratin 18. 
Though before such markers can be implemented into the clinic, further characterization is 
needed regarding the sensitivity and specificity of these markers as well as their stability in 
body fluids for reliable detection (58, 59). 
1.2.4 Risk factors 
A plethora of factors have been proposed to affect the susceptibility to idiosyncratic DILI and 
the subsequent outcomes. These include characteristics of the drug, environmental factors, 
and genetic and non-genetic factors of the host. Drug-specific risk factors include high 
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lipophilicity (60), high daily oral doses (60, 61), and the propensity to cause interactions with 
other drugs (62, 63). Extensive hepatic metabolism has also been identified as a risk factor in 
the pathogenesis of DILI (64, 65). Reactive drug metabolites can covalently bind to proteins, 
forming drug-protein adducts that could induce direct toxicity or elicit an immune response 
(66). In addition, the liability of drugs to inhibit certain bile acid transporters, including the 
bile salt export pump (BSEP) (67) and multi-drug resistance proteins (MRP) 2-4 (68), is 
considered a risk factor for liver injury. Specifically, the potency to inhibit BSEP was higher 
among drugs causing cholestatic or mixed patterns of liver injury than among drugs causing 
hepatocellular injury (67).  
A variety of non-genetic host risk factors have been proposed including age, gender, 
comorbidities, and concomitant drug use. Although it is well recognized that aging induces 
pharmacokinetic and pharmacodynamic changes, agedness has not univocally been identified 
as a risk factor for idiosyncratic DILI (69). However, DILI with persistent or chronic hepatic 
abnormalities are more often seen in older patients, possibly due to the age-related reduction 
in tissue repair capacity (70, 71). Conversely, young patients under the age of two appear to 
be at increased risk for hepatotoxicity induced by valproic acid (72). It is considered 
controversial as to whether females in general are at higher risk to develop DILI, though 
strong evidence is provided that female patients presenting with DILI are more likely to 
progress to ALF (73). Age and gender differences are also found in the clinical phenotype of 
DILI: where cholestasis was more frequent in male patients over the age of 60, hepatocellular 
injury was more frequent in younger female patients (74), though due to the limited study 
size further validation of this observation is needed. Underlying chronic viral infections, e.g. 
with hepatitis C or human immunodeficiency viruses, have been associated with an increased 
risk of liver injury caused by antituberculosis drugs (75, 76). Lifestyle factors that are thought 
to play a role in the pathogenesis of idiosyncratic DILI include diet, alcohol consumption, 
and the gut microbiome, but these are not currently recognized as bona fide risk factors (77).  
Genetic variation in drug-metabolizing enzymes (DMEs) and drug transporters may result in 
an imbalance between formation and detoxification of reactive drug metabolites or impaired 
hepatic transport, ultimately predisposing the patient to specific drug hepatotoxicities. 
Genetic studies on idiosyncratic DILI are challenging, due to its rare incidence, the number of 
different drugs implicated in DILI, and the wide range of liver injury phenotypes (78). 
However, significant progress has been made in recent years, employing both genome-wide 
association studies (GWAS) and candidate gene association studies using a priori 
information. A well-established example is the association between certain N-
acetyltransferase 2 (NAT2) genotypes and isoniazid-induced liver injury, which has been 
observed in multiple independent studies (79-81). Possession of the *2 allele of uridine 
diphosphate-glucuronosyltransferase 2B7 (UGT2B7) appears to constitute a risk factor for 
diclofenac-induced liver injury (82, 83). Several polymorphisms in ABCB11, which encodes 
BSEP, have been proposed to increase the risk of liver injury from different drugs (84-86). 
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However, conflicting reports exist (87) and additional studies in larger and varied populations 
are needed to validate these findings.  
Certain human leukocyte antigen (HLA) alleles may also constitute important risk factors for 
idiosyncratic immune-mediated DILI reactions since the major histocompatibility complex 
proteins mediate antigen presentation essential for T cell immune responses. To date, only 
few drug-specific HLA risk alleles have been uncovered by GWAS. Examples include  
HLA-B*57:01 with flucloxacillin (odds ratio (OR) = 80) (88), HLA-DQA1*02:01 with 
lapatinib (OR = 9) (89), and HLA-B*35:02 with minocycline (OR = 29.6) (90). Further 
characterization of the heterogeneity of the genetic risk factors predisposing a patient to 
idiosyncratic DILI is awaited. In particular, whole genome sequencing could provide novel 
insights into the role of rare variants (91). However, given that especially HLA genes are 
hyperpolymorphic and the fact that additional risk factors may be required, prospectively 
predicting idiosyncratic DILI events prior to drug prescription remains extraordinarily 
challenging. 
1.3 DRUG-INDUCED PHARMACOKINETIC ALTERATIONS 
1.3.1 Drug-drug interactions 
Drug-drug interactions (DDIs) are highly concerning in the clinic with regard to unfavorable 
therapeutic responses and occurrence of ADRs. While the list of potential DDIs is extensive, 
many are not necessarily clinically relevant (92). Still, clinically important DDIs frequently 
occur and are a major source of ADRs (93), including cases of fatality (94, 95), and have 
been the reason for multiple restricted-use warnings and post-marketing drug withdrawals 
(96). DDIs are expected to only become a bigger clinical issue as drug prescription and multi-
drug therapies are steadily on the rise, which is in part driven by the high rates of 
comorbidities and the growing aging population (97-99). Analysis of drug use in the United 
States between 2007 and 2010 revealed that 47.5% of the population take at least one 
prescription drug, while 10.1% take five or more simultaneously (100). Elderly patients are 
especially at an increased risk to develop DDI-related ADRs due to the increased prevalence 
of polypharmacy and age-related changes impacting on drug pharmacokinetics (101-104). 
This growing problem is also recognized by regulatory agencies and accordingly the 
European Medicines Agency (EMA) recently issued a strategy to report ADRs and to identify 
common DDIs or drug-disease interactions in the elderly (105). In theory, DDIs could be 
considered predictable and preventable (106-108), yet medication prescription errors still 
frequently occur, in part due to inadequate knowledge about DDIs of healthcare providers 
(109, 110). In addition, various factors are known to influence the likelihood of DDI 
occurrence including age, genetic background, and disease and nutritional statuses, which 
make accurately predicting patient-specific clinical outcomes highly complex (111). 
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1.3.2 Cytochrome P450-mediated drug interactions 
DDIs influencing pharmacokinetic parameters result in changes in the absorption, 
distribution, metabolism, and excretion (ADME) profile of the affected drug, characterized 
by altered plasma drug concentration-time profiles (112). The vast majority of DDIs are 
metabolism-mediated and involve induction or inhibition of DMEs or transporters. The 
clinical consequences may include 1) reduced or loss of intensity or duration of drug effects 
due to decreased systemic drug exposure, 2) enhanced efficacy due to increased systemic 
drug exposure, or 3) development of ADRs due to either increased systemic drug exposure or 
increased formation of reactive drug metabolites (113, 114). The majority of clinically 
significant DDIs documented in the literature are mediated via changes in the activity of 
cytochrome P450 (CYP) enzymes (115-117). This is not surprising given that they are 
responsible for the metabolism of ~75% of all drugs (118). In one report, the prevalence of a 
potential CYP-mediated DDI in elderly patients taking 5 or more drugs was estimated at 
80%, and the probability of at least one CYP-mediated DDI was 50% when taking 5-9 drugs, 
which increased to 100% when taking 20 or more drugs (119). The impact of CYP-mediated 
DDIs has long been recognized and both the FDA and EMA provide extensive guidelines on 
approaches to evaluate potential clinical DDIs through CYP induction or inhibition studies in 
drug development (120). 
The CYP superfamily is involved in many important biological processes including 
cholesterol homeostasis as well as the metabolism of steroids, fatty acids, and prostaglandins 
(121, 122). CYPs are however predominantly known for catalyzing the oxidative metabolism 
of drugs and other xenobiotics (123). Although 57 putatively functional human CYP enzymes 
exist (124), only 8 isoenzymes are considered to be clinically important (i.e.  CYP1A2, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) (125). 
Significant inter-individual differences in basal CYP expression and activities exist, owing to 
a wide variety of factors including age, gender, genetic polymorphisms, epigenetic changes, 
disease state, and diet (126, 127). Likewise, tremendous inter-individual variabilities in 
response to CYP induction and inhibition are observed due to both environmental and 
physiological factors (128). 
CYP-mediated DDIs arise more frequently from CYP inhibition than from CYP induction 
and the clinical outcomes are often more serious (129, 130). Inhibition of CYP metabolism is 
an instantaneous and direct reaction that can be either reversible or irreversible in nature and 
may result in increased plasma concentrations of the affected drug, leading to toxicity (131). 
A classic example is the ketoconazole-mediated inhibition of CYP3A4-mediated metabolism 
of terfenadine leading to prolonged electrocardiographic QT intervals (132), increasing the 
risk for torsades de pointes. CYP induction is considered to be less of a safety issue but can 
result in therapeutic failures due to increased metabolic clearance of the victim drug and 
therefore is an undesirable property that should be considered during drug development 
(133). Though not as common, CYP induction can also result in toxicity due to increased 
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formation of reactive drug metabolites. In addition, toxicity may arise if clinicians do not 
recognize the need to reduce the dose of the induced medication upon discontinuation of the 
inducing agent, as can be the case when patients self-medicate with the CYP3A4 inducing 
agent St John’s wort (134, 135). CYP induction is a much slower and indirect process, most 
commonly occurring through increased gene transcription or rarely through stabilization of 
the mRNA or protein (as is the case for CYP2E1 (136)). These processes involve a multitude 
of molecular players, and CYP induction responses are consequently subject to large inter-
individual differences (137). Besides impacting on other medications, drugs can also 
unfavorably induce their own metabolism (i.e. auto-induction), which is also pertinent to 
consider during drug development. This is exemplified by the case of AZD1208, a PIM 
kinase inhibitor developed for the treatment of acute myeloid leukemia (138). This compound 
was recently terminated from development because of its unfavorable pharmacokinetic 
profile observed in the clinic, which was attributed to the acceleration of its own metabolism 
through CYP3A4 induction leading to unstable plasma concentration profiles (139, 140). 
1.3.3 Molecular mechanisms of CYP3A4 induction 
DDIs involving CYP3A4 are especially important to consider, as it is the predominant CYP 
isoform expressed in the human liver and intestine and is implicated in the metabolism of 
many marketed drugs (141). Various drugs currently used in the clinic are known to induce 
CYP3A4 (e.g. rifampicin (142), phenobarbital (143), and phenytoin (144)). On a molecular 
level, CYP3A4 induction is thought to predominantly occur via activation of the nuclear 
receptor (NR) pregnane X receptor (PXR; NR1I2) (145). Upon activation, PXR forms a 
heterodimer with the retinoid X receptor (RXR) in the nucleus. The PXR/RXR complex then 
binds to distinct responsive elements within the promoter region of the CYP3A4 gene to 
regulate its transcription (146, 147). Expression of CYP3A4 is also under the control of the 
constitutive androstane receptor (CAR; NR1I3) (148). Upon activation, CAR translocates 
from the cytoplasm to the nucleus to form a heterodimer with RXR that binds to specific 
responsive elements in the promoters of its target genes to control their transcription. It is 
noteworthy to mention that significant species differences exist in the response to CYP 
inducers, owing to cross-species variations in the ligand-binding domain sequences of PXR 
and CAR (149). For example, rifampicin is a potent human PXR activator but has little effect 
on mouse PXR (150). Reciprocally, TCPOBOP is a potent mouse CAR ligand but does not 
activate human CAR (151). These prominent differences represent a challenge in drug 
development since evidently animal models cannot be employed to screen for human CYP 
induction (152). 
In humans, PXR and CAR can be activated by a variety of structurally diverse compounds, 
some of which act both on PXR and CAR (e.g. phenobarbital) (153, 154). Moreover, in 
addition to CYP3A4, PXR and CAR regulate the expression of a largely overlapping set of 
target genes, including CYP2B6, CYP2C9, CYP2C19, and CYP3A5 (155). However, 
differences in their preference of gene regulation exist. PXR displays strong binding to all 
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functional responsive elements in the promoters of both CYP2B6 and CYP3A4, whereas CAR 
only weakly binds to the ER6 motif in CYP3A4, but strongly binds to the DR4 motif in the 
phenobarbital responsive element module (PRBEM) in the promoter region of CYP2B6, 
explaining its preferential induction of CYP2B6 over CYP3A4 (156, 157). Furthermore, an 
important difference between these NRs is that CAR can constitutively transactivate target 
genes in the absence of activators, while PXR cannot (158). CAR activity is normally 
restrained through cytosolic sequestration (159) but upon stimuli, either through direct ligand 
binding or indirect activation, CAR translocates to the nucleus to regulate the expression of 
its target genes (160-163). On the other hand, PXR activation is conventionally thought to 
depend on direct ligand binding. However, reports of indirect regulation of PXR-mediated 
induction of CYP3A4 by protein kinase A (PKA) (164) and protein kinase C (PKC) (165) 
exist, possibly through altering the phosphorylation status of PXR. Therefore, it can be 
anticipated that additional ways of indirect PXR activation resulting in CYP3A4 induction 
exist. 
Besides PXR and CAR, other NRs reported to be directly or indirectly involved in the 
regulation of CYP3A4 expression include the vitamin D receptor (VDR) (166) and the 
glucocorticoid receptor (GR) (167). In addition, the liver-enriched transcription factor 
hepatocyte nuclear factor 4 alpha (HNF4α) has been shown to regulate PXR- and CAR-
mediated transcriptional activation of CYP3A4 (168). Various NRs are known to share the 
same responsive elements in the promotors of their target genes and to compete for common 
coactivators and corepressors, which are necessary for the tuning of the transcriptional 
response (169, 170). For example, PXR and CAR share several coactivators, including the 
peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) and the 
steroid receptor coactivators 1 and 2 (SRC1-2) (171). As such, a complex cross-talk between 
these NR signaling pathways is created. 
1.4 PRECLINICAL LIVER MODELS 
Clinical safety issues are currently one of the primary reasons for the attrition of drug 
candidates in phases I and II (24, 27, 172, 173). A recent review of AstraZeneca’s 
productivity remarkably indicated that for compounds terminated in the clinical phase due to 
safety issues the level of confidence in their preclinical safety profile was low, whereas when 
confidence levels were high no compounds were terminated in the clinical phase because of 
safety issues but rather due to efficacy issues (173). Adding to this observation, Morgan et al. 
(2018) note that ‘…there remain continued instances of idiosyncratic or unexplained toxicity. 
We and others continue to explore new in vitro and in vivo models to improve translation to 
the clinic’ (24). The introduction of drug metabolism and pharmacokinetic studies in drug 
development has led to increased understanding of the pharmacokinetic/pharmacodynamic 
(PK/PD) properties of drug candidates. Still, analysis of AstraZeneca’s attrition data from 
2005 to 2010 revealed that unfavorable PK/PD profiles were the cause of 15% of all project 
closures in phase I (173). 
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The liver is persistently being reported as one of the major organ systems associated with 
(late-stage) closures of drug development programs and post-marketing withdrawals (173, 
174). Recent examples include the attrition of fasiglifam, which was terminated only in phase 
III due to concerns about liver safety (175, 176), the termination of AZD1979 due to 
unexplained ALT elevations in the clinic (24), and the restricted-use warnings of flupirtine, 
pazopanib, and temozolomide due to signs of hepatotoxicity that remained unnoticed during 
drug development (177). Not surprisingly, the EMA and FDA recognize the problem of drug 
hepatotoxicity and accordingly have issued guidelines to aid in the assessment and 
interpretation of DILI signals during the preclinical stage of development (178). The recent 
termination of AZD1208 because of its unfavorable PK profile in humans (i.e. CYP3A4 auto-
induction) that was not identified in the preclinical phase of development (139, 140) also 
underlines the shortcomings of the current preclinical models to accurately predict drug PK 
profiles. Undeniably, refinements of the preclinical strategies to predict the metabolic and 
toxicological profiles of drug candidates need to be made. In the following paragraphs 
conventional preclinical models and emerging novel models to assess the impact of drugs on 
the human liver are discussed. 
1.4.1 Animal models 
Safety tests in two or more different animal species are required before a drug candidate can 
proceed to being tested in the clinic (179). Preclinical assessments in animals could provide 
essential information regarding the PK/PD and toxicological profiles of drug candidates. 
Retrospective analyses, however, indicate that the concordance between animal and human 
toxicity is poor, with true positive human toxicity concordance rates of 63% and 43% for 
non-rodent and rodent models, respectively (180). Furthermore, animals may show increased 
sensitivity towards toxicity of drugs at doses that are considered safe for humans (e.g. APAP 
(mice) and ibuprofen (dogs)) (39). With specific regard to DILI, the presence of toxicity in 
animal models does not typically halt the progression of drug candidates into clinical 
development unless clear dose-dependent indicators are seen (181), due to the fact that 
preclinical prediction of clinical hepatotoxicity is notoriously poor (182, 183). This may stem 
from the apparent and significant inter-species variation in xenobiotic metabolism (184), 
explained by differences in the structure, substrate affinities, catalytic activities, and induction 
of DMEs (185, 186). Consequently, the use of animal models to predict drug metabolism and 
hepatotoxicity events in humans is limited. 
The case of fialuridine is an excellent example of how inter-species differences can cause 
detrimental effects in the clinic. This drug, a nucleoside analogue developed for the treatment 
of chronic hepatitis B virus infection, showed great promise concerning its toxicity profile in 
preclinical in vivo studies in mice, rats, and cynomolgus monkeys (187). Clinical phase I 
studies in patients were promising, resulting in significant suppression of serum hepatitis B 
virus DNA levels (188) and hence a subsequent phase II trial with 15 patients was started in 
1993. Unexpectedly, however, in the 13
th
 week of treatment, one patient developed liver 
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failure and lactic acidosis, leading to the termination of the study. Severe hepatotoxicity with 
progressive lactic acidosis was observed in seven patients, resulting in the death of five and 
two others requiring emergency liver transplants. An additional three patients displayed mild 
hepatotoxicity. Analyses of the hepatic tissues revealed fat accumulation in the hepatocytes 
and abnormal mitochondria (189). Additional follow-up experiments confirmed the absence 
of toxicity in rodents after 10 weeks of treatment at 1,000-fold concentrated doses compared 
to those used in humans (187). Later mechanistic evaluations in vitro indicated that species 
differences in the subcellular expression pattern of the equilibrative nucleoside transporter 1 
(ENT1), for which fialuridine is a substrate, may account for the observed human-specific 
toxicity of fialuridine. Besides expression on the plasma membrane, this transporter was 
found to be exclusively expressed on the human, but not mouse, mitochondrial membrane. 
The ENT1-mediated uptake of fialuridine in human mitochondria may explain its selective 
mitochondrial toxicity exerted in humans (190, 191). Indeed, fialuridine-induced 
hepatotoxicity could exclusively be detected in chimeric mice with humanized livers (192). 
1.4.2 Conventional in vitro models 
Recommendations for toxicity testing made by the U.S. National Academy of Sciences in 
2007 urged a paradigm shift from extensive usage of in vivo models to in vitro systems 
employing human primary cells or cell lines to not only decrease animal usage but also to 
obtain increased efficiency and better mechanistic understanding of human ADRs (193). To 
date, a multitude of different human liver-derived in vitro models have been developed. 
Immortalized human liver cell lines, such as the HepG2 or HepaRG cell lines, are often 
employed to obtain an initial indication of the crude DILI risk of drug candidates using 
supraphysiological drug concentrations (194-197). Though these cell lines are well-
established, cheap, easy to handle, and allow generation of reproducible data in a high-
throughput setting, they are limited by their immature phenotypes. CYP activities and 
expression of DMEs and hepatic transporters are drastically lower in these cell lines 
compared to primary human hepatocytes (PHH) (198-200), which is also reflected in their 
reduced sensitivity towards drug hepatotoxicity compared to PHH and the lack of CYP 
inducibility in the case of HepG2 cells (200, 201). To overcome the limited liver-specific 
functionalities, cell lines overexpressing specific DMEs or NRs have been established for 
improved toxicity prediction and assessments of CYP enzyme induction (202-204), yet the 
overall molecular phenotypes still remain drastically different from the human liver in vivo. 
PHH have long been considered the gold standard cell source to create in vitro liver models 
(205). When kept in suspension, gene expression patterns are well maintained and are 
comparable to those observed in the liver of origin (206). PHH suspension cultures are 
mainly useful for the prediction of metabolic clearance and CYP inhibition-mediated DDIs 
(207-210), while assessments of drug hepatotoxicity and CYP induction are not feasible due 
to their limited life span (i.e. a couple hours) (211). When seeded on a layer of rat-tail 
collagen as two-dimensional (2D) monolayers, PHH can be kept viable for several days in 
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culture. However, the plating on a rigid substratum induces major morphological and 
functional alterations (212). Cells flatten, cell-cell contacts are reduced, and the loss of 
polarity hampers formation of bile canalicular networks and leads to a rapid reduction in 
DME expression and decline in metabolic activities (206, 212-214). Nevertheless, PHH 2D 
monolayers are still widely used for drug hepatotoxicity studies (215). Reports on their 
sensitivity towards DILI vary greatly but in general are not considered satisfactory (200). In 
addition, they are often also the model of choice to evaluate drugs for their CYP induction 
liability (216, 217). Yet, the recent case of the termination of AZD1208 from development 
due to unexpected CYP3A4 auto-induction observed in vivo, which was not identified in 
preclinical studies employing 2D monolayer cultures of three different PHH donors (140), 
questions the robustness of this model to make accurate predictions of clinical CYP 
induction. 
1.4.3 Emerging novel in vitro models 
A relevant in vitro liver model should possess a variety of characteristics to study liver 
biology and to assess the metabolic and toxicological profile of drugs. We (218) recently 
formulated that a system should: 
 Closely reflect in vivo liver physiology and morphology 
 Remain viable and functionally stable for multiple weeks in culture  
 Allow co-culturing of all liver cell types, i.e. parenchymal and non-parenchymal cells  
 Allow taking genetic predispositions into consideration 
 Be compatible with higher throughput applications 
 Use low cell numbers to reduce costs and minimize material usage 
In recent years, much emphasis has been placed on moving from the conventional simple 2D 
hepatocyte culture systems to more organotypic culture systems that include both hepatic 
parenchymal and non-parenchymal cell (NPC) types. This enables cells to adopt a more 
tissue-like structure, where homo- and heterotypic cell contacts and interactions with the 
environment can be made. Accordingly, these improvements positively impact on the cellular 
phenotypes in vitro (219, 220). Hepatocytes in vivo are highly polarized epithelial cells that 
form thin branching hepatic plates, usually of only one cell thickness, which are separated 
from the hepatic sinusoidal vascular network by the space of Disse. In the liver sinusoids, 
different NPC types reside including Kupffer cells, liver sinusoidal endothelial cells (LSECs), 
as well as various lymphocytes (221). Hepatocytes contain distinct canalicular-apical 
domains that are separated from the sinusoidal-basolateral domains by tight junctions. The 
basal membranes of hepatocytes are in contact with extracellular matrix (ECM) components 
and hepatic stromal stellate cells in the blood plasma-filled space of Disse. The lateral 
membranes of hepatocytes are used to establish contact with neighboring hepatocytes. During 
liver development, hepatocytes form apical domains enclosed by tight junctions at the lateral 
membrane between two adjacent cells which merge together to form a complex bile 
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canalicular network later in development (222-225). Hepatocyte polarity is critical for proper 
liver function and loss of polarity is associated with major pathophysiological changes 
including liver diseases such as cholestasis and hepatocellular carcinoma (226). 
One of the first attempts made to reestablish hepatocyte polarity in vitro is based on culturing 
hepatocytes within two layers of ECM components (most commonly collagen or Matrigel®), 
termed sandwich cultures (227). In this configuration, cell spreading and formation of stress 
fibers are reduced, cell-cell contacts are improved, hepatocytes secrete a variety of ECM 
proteins, and importantly hepatocyte polarity is reestablished (228, 229). These changes 
positively impact on the viability and functionality of hepatocytes (230). Importantly, over 
the course of several days functional bile canalicular networks are created (231), which is a 
critical aspect for assessments of drug PK profiles (232). PHH sandwich cultures are 
therefore often the model of choice for studies of hepatobiliary drug transport and drug-
induced cholestasis (233, 234). A large toxicity study in PHH sandwich cultures using 200 
DILI-positive and 144 DILI-negative compounds screened at 100xCmax levels impressively 
detected no false positives, yet only 51% sensitivity was achieved (235). This rather low 
sensitivity may be due to the acute 24 hour drug exposure setting as well as the fact that 
sandwich culturing cannot prevent hepatocyte dedifferentiation, as typical patterns of 
epithelial-to-mesenchymal transition (EMT) are observed after two weeks of culture (236). 
Moreover, expression of DMEs has been reported to be unstable over time (237) and 
activities of important CYPs are gradually lost during the first days of culture (238). 
Substantial advances have also been made with regard to the fabrication of functional 
microscale liver subunits where the microenvironment can be precisely controlled, which has 
been shown to positively impact on the stability and functionality of cells (239-241). A 
notable example is the development of micropatterned co-cultures of PHH and supportive 
cells. In this model, PHH are cultured on 2D collagen-coated islands that are surrounded by 
supportive stroma (i.e. mouse embryonic 3T3-J2 fibroblasts), thereby allowing the 
establishment of important heterotypic interactions between the hepatocytes and stromal 
cells, which are of importance for hepatocyte functionality (242). Accordingly, expression of 
DMEs, CYP activities, secretion of albumin and urea, and functional bile canalicular 
networks could be retained for several weeks in culture, and hepatotoxicity was predicted 
with 66% sensitivity and 90% specificity in a screen of 35 DILI-positive and 10 DILI-
negative compounds tested at 100xCmax levels (242, 243). This model has since been used for 
various applications, including studies of drug metabolism (244-246), host-pathogen 
interactions (247), and nutritional state changes (248). Further improvements were recently 
made by establishing co-cultures of PHH with Kupffer cells to study the impact of pro-
inflammatory cytokines on hepatic functionality (249). However, the use of mouse 
embryonic non-liver-derived cells as stroma to support hepatocyte longevity and 
functionality, as well as the use of rat-tail collagen rather than liver-specific ECM reduce the 
human relevance. Furthermore, the 2D monolayer format of the hepatocyte islands limits the 
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physiological relevance of this model to mimicking hepatic cords rather than advanced 
hepatic sinusoidal structures (250).  
Numerous efforts have focused on further improving the physiological relevance in vitro by 
creating three-dimensional (3D) organotypic cultures, including scaffold-based or scaffold-
free multi-well plates and perfusion bioreactors (251-253). In 3D spheroid culture, 
hepatocytes spontaneously aggregate into tissue-like structures over the course of several 
days. Currently, the value of such systems has predominantly been illustrated with human 
liver cell lines. In relation to the respective 2D monolayer cultures, enhanced molecular 
phenotypes and liver-specific functionalities have been observed when HepG2 or HepaRG 
cells are cultured as 3D spheroids, which may lead to improved drug toxicity responses (254-
259). Though PHH are considered the most relevant cell source to mimic the human liver, 
few studies have evaluated their behavior in 3D spheroid culture. In a perfusion bioreactor, 
PHH spheroids formed functional bile canalicular networks, displayed stable CYP expression 
during 2 weeks of culture, and were in a long-term setting responsive towards 2 CYP 
inducers (260). In another study, responsiveness to drug toxicity of PHH spheroids cultured 
in a microscale bioreactor was shown using APAP as a model hepatotoxin (261). In these 
perfusion bioreactor set-ups, in vivo hemodynamics can be mimicked, physiological 
parameters (e.g. pH and oxygen levels) can be tightly controlled, and a continuous nutrient 
supply and removal of metabolic by-products is established (262). However, large cell 
numbers are required and the bioreactor set-up approach impedes higher throughput 
applications including drug toxicity screening. 
A static scaffold-free 96-well hanging drop system was developed a few years ago that 
represents a higher throughput approach requiring substantially fewer cells (263). In this 
system, randomly organized spheroid co-cultures of PHH and non-parenchymal Kupffer and 
endothelial cells showed stable viability and albumin production for 5 weeks in culture. 
Using 3 hepatotoxins it was shown that repeated-dose toxicity studies could be performed for 
up to 14 days (263). Using a set of 69 DILI-positive and 41 DILI-negative compounds, DILI 
was predicted with 59% sensitivity and 80% specificity in this system (264), indicating no 
substantial improvements compared to reports in PHH sandwich cultures and the 
micropatterned co-culture system mentioned earlier. In another study, PHH spheroids 
generated in a 384-well magnetic 3D culture system were evaluated as a novel high-
throughput model to assess CYP induction and inhibition (265). While basal CYP activities 
of PHH were higher in 3D spheroid culture compared to the corresponding 2D monolayer 
cultures, the response to a set of 6 prototypical CYP inducers and inhibitors was similar in 
both culture formats (265). Taken together, these studies provide proof-of-concept that PHH 
in 3D spheroid culture may have enhanced phenotypes and functionalities, whereas thorough 
evaluation of their responses to drugs has not been performed. 
Microfluidic liver-on-a-chip approaches open up the possibility to create highly organized 
hepatic microenvironments with tightly controllable dynamic flow conditions (266, 267). A 
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3D-configured microfluidic chip was recently constructed that enables configuring four 
relevant murine liver cell types (i.e. hepatocytes, stellate, Kupffer, and endothelial cells) into 
liver sinusoidal structures. This model was found suitable to study primary immune responses 
seen by neutrophil recruitment in the chip upon lipopolysaccharide (LPS) stimulation (268). 
Also promising is the construction of multiple organs-on-a-chips that allow studying delicate 
interactions between the liver and other organs. Interesting examples include, amongst others, 
a gut-liver chip to reproduce the first pass metabolism of drugs (269, 270), a liver-pancreatic 
islet chip as a type 2 diabetes mellitus model (271), a liver-kidney chip for assessment of drug 
nephrotoxicity dependent on hepatic metabolism (272), a skin-intestine-liver-kidney chip for 
long-term systemic drug toxicity testing (273), an intestine-liver-cancer-connective tissue 
chip for evaluating anti-cancer drug therapies (274), and an impressive proof-of-concept of 
13-organs-on-a-chip (275). The integration of 3D printing into these microfluidic chips is 
expected to further facilitate the establishment of micro-livers in vitro, since cells and ECM 
can be assembled in a layer-by-layer process and the spatial distributions of materials and 
cells can be tightly controlled in an automated manner (276-279). The downscaling enabled 
by these innovative technologies substantially reduces the number of cells needed, though 
also makes it more complex to control the culture environment. Furthermore, many of the 
microfluidic chips to date have relied on hydrophobic poly(dimethylsiloxane) (PDMS) 
scaffolds, although these can bind to lipophilic drugs and their metabolites which confounds 
drug exposures (280). In addition, the associated costs are high and the complexity of these 
systems affect the throughput and the ability to perform diverse biochemical analyses, 
limiting their current use in drug development (281, 282). 
An alternative source of liver cells that could overcome certain limitations of PHH (e.g. 
shortage of donors, originating from diseased livers, and the inability to be expanded in vitro 
(283)) are hepatocyte-like cells (HLCs) derived from induced pluripotent stem cells (iPSCs) 
(284, 285). Any somatic tissue can in principle be used to generate iPSCs and hence this 
enables retrospectively identifying underlying genetic risk factors that confer a patient 
susceptible towards idiosyncratic DILI. In addition, HLCs may be valuable to obtain a better 
understanding of disease processes and allow the potential identification of new therapeutic 
interventions (286, 287). However, with the current differentiation protocols HLCs do not 
reach mature hepatocyte phenotypes (288, 289). Instead, they display immature, fetal-like 
characteristics and expression of DMEs and activities of CYPs are drastically lower in 
comparison to PHH (290-293) and high expression of alpha-fetoprotein (AFP), a fetal 
hepatocyte biomarker, is frequently observed in these cultures (294). Like other liver cells, 
when maintained in 3D culture, the phenotypes of HLCs are improved, as seen by enhanced 
expression of DMEs, increased CYP activities, improved CYP induction responses, and 
formation of bile canalicular networks (295, 296). Recent studies showcased the utility of 
HLCs to assess inter-individual differences regarding CYP metabolism (297) and drug 
toxicity sensitivity (298, 299). Furthermore, their value in studying the mechanisms 
underlying idiosyncratic DILI was recently demonstrated. HLCs derived from iPSCs 
  15 
generated from patients presenting with pazopanib-induced hepatotoxicity displayed greater 
sensitivity towards the toxicity of this drug in vitro compared to HLCs from patients 
insensitive to pazopanib hepatotoxicity (300). 
Collectively, it is evident that complex organotypic liver models are a major research interest 
and consequently the progress in the field is rapid. Ample evidence has been provided that 
the physiology and functionality of liver cells cultured in these systems more closely 
resemble the liver in vivo. However, most studies have employed human liver cell lines or 
primary rat hepatocytes as cell sources. While HLCs derived from iPSCs are a promising 
avenue, improved differentiation protocols are needed and as such primary human liver cells 
remain the preferred cell source to model the human liver in vitro. Comprehensive 
characterization of primary human liver cells with regard to their molecular phenotypes and 
functionalities as well as their drug responses in these complex 3D culture systems is awaited. 
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2 AIMS 
The overall aim of this thesis was to develop and characterize a novel in vitro 3D spheroid 
culture system comprised of PHH for assessments of drug metabolism and hepatotoxicity. 
 
The specific aims were to: 
 
I. Study the early changes of the dedifferentiation process of PHH in 2D monolayer 
culture 
 
II. Characterize the molecular phenotypes and functionalities of PHH in 3D spheroid 
culture and assess the long-term stability  
 
III. Assess the suitability of PHH 3D spheroid cultures as a screening model for DILI, 
with emphasis on reactions that may be delayed in onset 
 
IV. Assess the suitability of PHH 3D spheroid cultures to detect and study drug-induced 
cholestasis  
 
V. Study the differences between PHH in sandwich and 3D spheroid culture for 
prediction of drug-induced cholestasis 
 
VI. Assess the suitability of PHH 3D spheroid cultures to detect the liability of drugs to 
induce CYP3A4
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3 RESULTS AND DISCUSSION 
3.1 ALTERATIONS OF THE LIVER ARCHITECTURE MAJORLY IMPACT ON 
HEPATOCYTE PHENOTYPES IN VITRO (STUDIES I AND II) 
PHH rapidly lose their liver-specific functionalities when cultured as 2D monolayers in vitro 
due to the hepatocytes undergoing dedifferentiation (213, 214). This greatly hampers the 
ability to accurately study liver biology as well as to predict drug responses. In-depth 
characterization of this dedifferentiation process is needed to formulate strategies to improve 
hepatic phenotypes in vitro and to increase the overall understanding of hepatocyte plasticity.  
In study I, we characterized the dedifferentiation process of PHH during the first 24 hours of 
cultivation as 2D monolayers using comprehensive transcriptomic and proteomic analyses. In 
this period, 4,042 differentially expressed transcripts were identified (Fig. 1A). The 
transcriptional changes could be grouped into an early (< 4 hours) and late  
(> 16 hours) response. Pathway analyses of the differentially expressed genes and proteins 
revealed early changes in immunity and energy balance, whereas changes in major metabolic 
pathways occurred later. Already 16 hours after cultivation, changes in the expression 
patterns of important ADME genes were observed, including downregulation of various 
CYPs and NRs (Fig. 1B).  
 
             
Figure 1. PHH rapidly dedifferentiate within the first 24 hours in 2D monolayer culture. (A) Heatmap 
showcasing differentially expressed genes in PHH from five different donors (indicated by number).  
(B) Heatmap showcasing average expression patterns of ADME genes in PHH from three different donors. 
Reproduced from paper I. 
We also observed that changes in the expression of non-coding RNAs preceded the changes 
in the expression of coding RNAs. Additional mechanistic investigations revealed an 
important role for microRNAs in driving hepatocyte dedifferentiation. The results from study 
I, as well as other studies (214, 301), clearly demonstrate that in 2D monolayer culture PHH 
rapidly lose their mature phenotype. The reduced physiological relevance of the 2D 
monolayer culture format is thought to be a key reason for the rapid dedifferentiation of PHH. 
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Current efforts are therefore focused on better mimicking the structural organization of the 
liver in vivo using diverse 3D culture strategies. Preliminary indications suggest that PHH in 
3D spheroid culture may have improved phenotypes, but extensive characterizations had not 
been performed to date.  
In study II we aimed to comprehensively characterize 3D spheroid cultures of PHH with 
regard to molecular phenotypes and drug responses. Because the 96-well Gravity PLUS
TM
 
Hanging Drop System had previously been successfully used to generate multi-liver cell type 
spheroids (263), we first employed this platform to generate 3D spheroid cultures of PHH. 
However, despite extensive optimization efforts, this system was not deemed feasible in our 
hands, amongst others due to the technique being extremely laborious and recurrent batch-to-
batch variations of the plates affecting data reproducibility. Therefore, we employed 
Corning® Costar® 96-well Ultra-Low Attachment plates for spheroid formation. These 
plates are coated with a hydrophilic, neutrally charged hydrogel that prevents cells from 
attaching and forces them in suspension, thereby allowing spontaneous aggregation of the 
cells into spheroids. Using this platform, PHH robustly formed a single spheroid per well of 
consistent size (1,500 cells/well, ~200 µm diameter) after 4-5 days in culture and were 
deemed mature from day 7 (Fig. 2). 
 
 
Figure 2. PHH spontaneously self-aggregate into compact 3D spheroid structures during the first week of 
culture. Scale bar = 100 µm. Reproduced from paper II. 
We then compared the proteomes of PHH in 3D spheroid culture (day 7 after seeding when 
spheroids had formed) to 1) the proteomes found in the human liver in vivo and 2) the 
proteomes of PHH when cultured as 2D monolayer after short-term (24 hours) and long-term 
(7 days) culture. The proteomes of PHH in 3D spheroid culture closely clustered together 
with the proteomes of the liver in vivo, whereas the proteomes of PHH in 2D monolayer 
culture were already drastically different after 24 hours (Fig. 3A). In line with the findings 
from study I, pathway analyses revealed major changes in metabolic pathways in PHH 2D 
monolayer culture, whereas few changes were observed in PHH 3D spheroid culture. 
Furthermore, using whole proteome analyses we found that PHH in 3D spheroid cultures 
retained their inter-individual variability, since 3D spheroid cultures from PHH clustered 
more closely together with the respective liver of origin than with the livers or 3D spheroid 
cultures from PHH from other donors (Fig. 3B). 
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Figure 3. PHH in 3D spheroid culture, but not in 2D monolayer culture, closely resemble the human liver in vivo 
at the proteome level. (A) Heatmap showcasing differentially expressed proteins (n = 574). (B) Whole proteome 
analyses of PHH in 3D spheroid cultures and the respective liver of origin. Reproduced from paper II.  
3.2 MOLECULAR PHENOTYPES OF PHH ARE STABLY MAINTAINED IN 3D 
SPHEROID CULTURE FOR MULTIPLE WEEKS (STUDY II) 
Having confirmed that PHH in 3D spheroid culture closely reflect the human liver in vivo, we 
investigated in study II the stability of the system during long-term culture regarding 
morphology, viability, and liver-specific functionalities. H&E staining demonstrated long-
term preservation of spheroid morphology, though spheroids were noticeably smaller at day 
35 compared to day 8 (Fig. 4A). This was associated with both a gradual increase in spheroid 
compaction as well as a small measure of continuous cell death. Using three different donors, 
we found that PHH in 3D spheroid culture could be maintained viable for at least four weeks 
after aggregation. Albumin secretion, an important liver-specific function, was stable during 
this period too, with a noticeable decline only at day 35. Interestingly, we found evidence of 
hepatic zonation patterns in the PHH spheroids, seen by the marginal overlap of CYP3A4 and 
albumin protein stainings (Fig. 4B). CYP3A4 is predominantly expressed in the perivenous 
region of the liver, whereas albumin is predominantly present in the periportal region (302). 
We hypothesize that different hepatocytes within a spheroid retain the phenotype and 
functionality according to which area in the liver they initially originated from.  
Reactive drug metabolite formation is considered an important mechanism of DILI (303). 
Hence, a reliable DILI screening model should amongst others display activity of important 
DMEs. Results from study II indicate that metabolic activities of CYP1A2, CYP2C9, 
CYP2D6, and CYP3A4 remain stable during four weeks of culture relative to the activities 
observed in PHH spheroids at day 8. Metabolic activity of CYP2C8 gradually decreased over 
time; the reason for this decline remains to be elucidated, though we consistently observed 
this trend with 3D spheroid cultures from different PHH donors, excluding inter-donor 
variability as the cause. Notably, remarkable variations in CYP activity between single 
spheroids formed from the same PHH donor were observed, indicating a certain degree of 
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heterogeneity of the system. This could be resulting from different ratios of perivenous vs. 
periportal hepatocytes within different spheroids, transdifferentiation of the cells, or variable 
oxygen levels across the culture plate. 
 
                       
Figure 4. PHH spheroids have stable phenotypes during four weeks of culture after aggregation. (A) H&E 
staining of spheroid morphology. (B) Immunohistochemical analysis of CYP3A4 and albumin protein 
expression. Scale bars = 100 µm. Reproduced from paper II.  
3.3 PHH SPHEROIDS ARE A SUITABLE SYSTEM TO SCREEN FOR DRUG-
INDUCED LIVER INJURY (STUDIES II AND III) 
There is currently an unmet but urgent need for novel preclinical DILI screening models. 
Since PHH in 3D spheroid culture possess in vivo-relevant phenotypes which can be stably 
maintained for several weeks, we assessed the potential of the system to retrospectively 
identify drugs with reports of causing liver injury in vivo. Since it is well known that DILI 
may be delayed in onset we specifically focused in study II on assessing the differences in 
sensitivity between acute (single 48 hour exposure) and chronic treatment (7 or 28 days of 
repeated exposure). Strikingly, the sensitivity of PHH in 3D spheroid culture towards the 
toxicity of all five hepatotoxins tested (amiodarone, bosentan, diclofenac, fialuridine, and 
tolcapone) markedly increased upon prolonging the drug exposures. While EC50 values for all 
drugs except tolcapone exceeded 30xCmax levels after a single 48 hour exposure, they 
decreased to 1-30xCmax levels (amiodarone, bosentan, and diclofenac) or below 1xCmax 
(fialuridine and tolcapone) after 7 days of repeated exposure. A further decrease in the EC50 
values of all drugs was observed after 28 days of exposure (Fig. 5A). Similar results were 
obtained in study III, where a decrease in the EC50 values of all hepatotoxins tested (i.e. 
acetaminophen, bosentan, chlorpromazine, tetracycline, and troglitazone) was observed when 
the exposures were extended from 8 to 14 days. 
An interesting finding of study II was the remarkable toxicity pattern of fialuridine upon 
prolonged exposure. A single 48 hour exposure at concentrations up to 100xCmax levels (Cmax 
= 1 µM) did not induce any toxicity. However, when PHH spheroids were repeatedly 
exposed for 7 or 28 days, fialuridine toxicity could be clearly detected at physiologically 
relevant concentrations (EC50 = 0.1 µM at 28 days) (Fig. 5B). Hepatotoxicity exerted by 
A B 
  23 
fialuridine appeared only after multiple weeks of treatment in vivo (189), presumably due to 
the gradual depletion of mitochondrial DNA leading to mitochondrial structural defects and 
lipid accumulation in hepatocytes (304, 305). This is an exemplar case of DILI that is delayed 
in onset. Such toxicity manifestations would likely be missed during the preclinical phase of 
development, as most currently used in vitro DILI screens are focused on acute drug toxicity 
assessments using a single exposure. Our findings therefore strongly argue to also assess the 
risk of delayed onset DILI events using a physiologically relevant and stable system, such as 
the PHH spheroid system presented here.  
 
 
          
Figure 5. PHH spheroids are a suitable platform to assess DILI events that may be delayed in onset. (A) EC50 
values of five hepatotoxins observed in PHH spheroids after a single 48 hour exposure or repeated exposures for 
7 or 28 days. (B) Toxicity profile of fialuridine in PHH spheroids after 48 hours (green), 7 days (red), and 28 
days (blue). Reproduced from paper II.  
3.4 CLINICAL PATTERNS AND MECHANISMS OF DRUG-INDUCED LIVER 
INJURY ARE REFLECTED IN PHH SPHEROIDS (STUDIES II AND III) 
The clinical phenotypes of DILI are extremely heterogeneous and may mimic virtually all 
primary liver diseases. In studies II and III we assessed whether specific patterns of DILI, 
including drug-induced steatosis and cholestasis, could be identified in the PHH spheroid 
system. In study II, we observed that upon a single 48 hour exposure to cyclosporine A 
(CsA), known to induce steatosis in vivo (306), neutral lipids were rapidly enriched in PHH 
spheroids. Interestingly, co-exposure to the antioxidant α-tocopherol (α-TOH) prevented the 
CsA-induced lipid accumulation (Fig. 6). This is in agreement with previous reports that 
antioxidants may have a beneficial role in mitigating CsA-induced liver injury (307, 308). 
Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide and 
its prevalence is rapidly increasing (309). Yet, currently no FDA-approved drug therapies 
exist for the treatment of non-alcoholic steatohepatitis (NASH), the more aggressive form of 
NAFLD (310). These preliminary findings suggest that the PHH spheroid system could be 
used to study hepatic steatosis, which if further characterized may be used as a model to 
screen for compounds that prevent, inhibit the progression, or reverse steatosis. 
A B 
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Figure 6. PHH spheroids reflect patterns of drug-induced steatosis. Cyclosporine A (CsA, 30 µM) rapidly 
induces neutral lipid accumulation after a single 48 hour exposure, a process that is prevented in the presence of 
the antioxidant α-tocopherol (α-TOH, 10 µM). Reproduced from paper II. 
In order to constitute a relevant system for cholestatic liver disease, the presence of bile 
canalicular networks with functional bile acid (BA) transporters is essential. Accordingly, in 
study III we evaluated the protein expression of multi-drug resistance protein 2 (MRP2) and 
the bile salt export pump (BSEP), two major canalicular BA transporters whose functional 
inhibition is often associated with drug-induced cholestasis (311), and evaluated their 
responsiveness towards a mixture of five human BAs (Fig. 7A). MRP2 was abundantly 
expressed in PHH spheroids, confirming our findings from study II which indicated stable 
MRP2 expression in PHH spheroids during four weeks of culture after aggregation. The basal 
expression of BSEP was low but could accordingly be induced by the BA mixture (30x 
concentrated compared to average human plasma levels), presumably through activation of 
the farnesoid X receptor (312). 
 
 
 
Figure 7. PHH spheroids can be used as a model for drug-induced cholestasis. (A) Immunohistochemical 
analysis of MRP2 and BSEP protein expression in the presence and absence of a 30x concentrated BA mixture 
for 8 days. (B) Assessment of BA accumulation using the fluorescently-labelled BA derivative tauro-nor-THCA-
25-DBD upon exposure to increasing chlorpromazine (CPZ) concentrations after 8 days of repeated treatment. 
Scale bars = 100 µm. Reproduced from paper III. 
A 
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We then focused on recapitulating patterns of drug-induced cholestasis in the PHH spheroid 
system using the model cholestatic compound chlorpromazine (CPZ) (313). Repeated 
exposure to CPZ for 8 days induced a dose-dependent accumulation of the fluorescently-
labelled BA derivative tauro-nor-THCA-25-DBD (Fig. 7B). Further mechanistic 
investigations revealed that CPZ inhibits ABCB11 mRNA expression (encoding BSEP) and 
disrupts the F-actin cytoskeleton which is of importance for proper insertion of BA 
transporters. These data are in line with previous observations in HepaRG cells (314). 
Interestingly, when PHH spheroids were exposed to CPZ in the presence of the BA mixture, 
patterns indicative of a synergistic increase in oxidative stress and BA toxicity were 
observed, seen by induction of mRNA expression of the Nrf2 target sulfiredoxin 1 (SRXN1) 
(315) and death receptor 5 (DR5) (316), respectively. The proposed mechanisms of CPZ-
mediated cholestatic hepatotoxicity are illustrated in Fig. 8. 
 
Figure 8. Currently identified mechanisms associated with chlorpromazine (CPZ)-induced cholestatic 
hepatotoxicity. Oxidative stress is rapidly observed upon CPZ exposure which has been associated with the 
disruption of the F-actin cytoskeleton (314). In combination with the inhibition of ABCB11 mRNA expression, 
BAs accumulate at toxic levels which pose additional oxidative stress and likely activate death receptor 
signaling, evident from the induction of death receptor 5 (DR5) mRNA expression. Reproduced from paper III. 
3.5 PHH SPHEROIDS CAN IDENTIFY THE LIABILITY OF DRUGS TO INDUCE 
CHOLESTATIC LIVER INJURY (STUDIES III AND IV) 
Cholestatic and mixed hepatocellular/cholestatic liver injuries are two serious clinical 
manifestations of DILI with high incidence rates (317). Currently, preclinical prediction of 
the liability of drug candidates to induce cholestasis is mainly aimed at assessing the potency 
to inhibit BSEP, which is achieved using either membrane vesicles or sandwich-cultured 
hepatocytes (318). However, the underlying mechanisms may be more complex and likely 
involve a multitude of players mediating BA homeostasis including NRs, BA conjugating 
enzymes, and other BA transporters (311). Furthermore, drug-induced cholestasis is often 
delayed in onset and subject to adaptive responses, making it challenging to predict (319). 
Therefore, there is a need for models that assess the risk for drug-induced cholestasis in a 
holistic manner with a focus on capturing toxicity events that may be delayed in onset. 
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In study III we assessed whether PHH spheroids could represent a suitable model to screen 
for the liability of drugs to induce cholestasis. To this end, we used a drug and concentrated 
BA mixture co-exposure strategy that was previously successfully employed in hepatocyte 
sandwich cultures (320). The risk of cholestasis is determined based on the drug’s ability to 
interfere with the disposal of an added BA mixture that is otherwise non-toxic to the cells. 
We observed a synergistic increase in toxicity upon co-exposure to a 30x concentrated BA 
mixture for hepatotoxins reported to be associated with cholestasis in vivo (bosentan, 
chlorpromazine, and troglitazone) (317), while this was not the case for the non-cholestatic 
hepatotoxins tested (acetaminophen and tetracycline). This indicates that the cholestatic drugs 
exclusively interfere with the disposal of the added BAs resulting in an increase in toxicity, a 
phenomenon that was more pronounced when the exposures were prolonged from 8 to 14 
days (Fig. 9A-B). Most notably, the cholestatic liability of chlorpromazine was only evident 
after 14 days of repeated exposure. Further validation of the model with 7 cholestasis-positive 
and 4 cholestasis-negative hepatotoxins in 3D spheroid cultures formed from a pool of 10 
PHH donors resulted in the correct classification of the cholestatic risk of all drugs after 14 
days of exposure with the exception of ticlopidine. The risk for developing ticlopidine-
induced cholestasis has been associated with an idiosyncratic immune-mediated component 
(321), which evidently cannot be captured in the PHH spheroid system. 
 
 
Figure 9. PHH spheroids can identify the liability of drugs to induce cholestasis after 14 days of repeated 
exposure. (A) Increased toxicity in the presence of an otherwise non-toxic 30x concentrated BA mixture is 
selectively observed for hepatotoxins with reports of causing cholestasis in vivo (bosentan, chlorpromazine, and 
troglitazone), (B) but not for hepatotoxins with no such reports (acetaminophen and tetracycline). Reproduced 
from paper III.  
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Since PHH sandwich cultures are considered the preferred model for studies of hepatobiliary 
transport and cholestasis (233), we sought to compare the PHH spheroid system to the current 
benchmark for assessing drug-induced cholestasis. The findings in study IV indicate that 
PHH sandwich cultures are indeed a robust model to detect the cholestatic risk of 
compounds, though remarkable differences between different PHH donors were apparent 
with regard to their sensitivity towards the cholestatic toxicity of certain drugs (i.e. bosentan, 
chlorpromazine, and troglitazone). Interestingly, a direct comparison of sandwich cultures 
and 3D spheroid cultures from the same PHH donor revealed that prolonged exposures in 3D 
spheroid culture could increase the sensitivity to detect the cholestatic risk of certain 
compounds. Chlorpromazine showed no cholestatic liability after a single 48 hour exposure 
in PHH sandwich cultures, nor after 72 hours exposure in 3D spheroid cultures of the same 
PHH donor. However, the synergistic toxicity of chlorpromazine and BAs could be unraveled 
when the exposures were extended in 3D spheroid culture, with the most pronounced effect 
visible after 14 days (Fig. 10A-C). The implications of this observation remain to be further 
investigated as the sandwich-3D spheroid comparison was only performed with one PHH 
donor, since other PHH donors either did not aggregate into spheroids or could not be stably 
maintained for extended culture periods. Additional comparative studies are needed to 
comment on the suitability and sensitivity of both systems for the prediction and study of 
drug-induced cholestasis. 
 
 
Figure 10. The cholestatic liability of chlorpromazine becomes increasingly apparent when the BA co-exposures 
are prolonged in 3D spheroid cultures of PHH. After 72 hours (A) and 7 days (B) no clear indications are 
evident, whereas after 14 days (C) chlorpromazine and BAs clearly pose synergistic toxicity. Adapted from 
manuscript IV. 
3.6 CLINICALLY RELEVANT CYP3A4 INDUCTION EVENTS ARE DETECTED 
IN PHH SPHEROIDS (STUDY V) 
CYP3A4 is involved in the metabolism of many clinically used drugs (141). Changes in its 
enzymatic activity, e.g. via induction, can therefore have detrimental outcomes including 
DDI-mediated therapeutic failures or development of ADRs. As such, early assessment of the 
liability of drug candidates to induce CYP3A4 during the preclinical phase of development is 
crucial. PHH 2D monolayer cultures are often the preferred model for CYP induction studies. 
However, the applicability of this model is questionable, as we previously observed in study 
I that PHH in 2D monolayer culture rapidly dedifferentiate and that expression of NRs, 
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important for mediating CYP expression, is drastically decreased within 24 hours. Therefore, 
in study V we examined whether the PHH spheroid system could constitute a more relevant 
and sensitive model to predict drug-mediated CYP3A4 induction. Induction of CYP3A4 
mRNA expression of a panel of 11 drugs with reports of inducing CYP3A4 activity in vivo 
could be clearly detected in PHH spheroids at physiologically relevant concentrations (at or 
below 1xCmax) and with magnitudes comparable to those found in vivo. In contrast, no 
induction of CYP3A4 mRNA expression was observed for a set of 13 drugs with no reports of 
inducing CYP3A4 in vivo (Fig. 11A-B). Applying the recommendations issued by the EMA 
to classify the liability of drugs to induce CYPs (322), the PHH spheroid system impressively 
achieved 100% sensitivity and 100% specificity. 
 
 
Figure 11. PHH spheroids correctly detect clinical CYP3A4 induction. (A) CYP3A4 mRNA expression is 
induced upon exposure to drugs reported to induce CYP3A4 activity in vivo, (B) whereas this is not the case 
upon exposure to drugs not known to induce CYP3A4 in vivo. All drugs were screened at 1xCmax levels, except 
probenecid (0.2xCmax). Reproduced from manuscript V. 
 
A crucial finding of this study was that PHH only when maintained in 3D spheroid culture, 
but not in 2D monolayer culture, could detect the CYP3A4 induction capacity of AZD1208 
(at 0.2xCmax) on mRNA and protein level at levels which were comparable to the magnitude 
of change observed for the prototypical inducer rifampicin (Fig. 12A-B). AZD1208 had 
eluded preclinical CYP3A4 induction screens employing HepaRG cells and 2D monolayer 
cultures of PHH from three different donors, but showed unexpected CYP3A4 auto-induction 
in the clinic leading to its termination (140). We hypothesized that AZD1208 induces 
CYP3A4 via an indirect mechanism rather than direct NR ligand binding since the latter 
mechanism can normally be identified in PHH 2D monolayer culture. Using gene 
knockdown experiments, we found that AZD1208 requires PXR and is partially dependent on 
CAR to exert its CYP3A4 induction. Preliminary indications suggest that ERK signaling is 
involved in this indirect pathway leading to CYP3A4 induction, which appears to be sensitive 
towards the presence of epidermal growth factor (EGF). Not surprisingly, ERK signaling is 
drastically altered in PHH 2D monolayers during hepatocyte dedifferentiation (212) which 
could explain the absence of AZD1208-mediated CYP3A4 induction in 2D monolayer 
culture. Collectively, our data suggest that the PHH spheroid system can robustly detect drug-
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mediated CYP3A4 induction at clinically relevant concentrations, and as such may constitute 
a valuable novel preclinical model to screen drug candidates for CYP3A4 induction. 
 
 
Figure 12. Detection of AZD1208-mediated CYP3A4 induction in PHH is dependent on the culture format. (A) 
PHH in 3D spheroid culture, (B) but not in 2D monolayer culture, can detect AZD1208-mediated induction of 
CYP3A4 mRNA expression at levels comparable to rifampicin. Percentages indicate the extent of induction 
relative to rifampicin. Reproduced from manuscript V.
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4 SUMMARY 
The findings in this thesis can be summarized as follows: 
 PHH dedifferentiation in 2D monolayer culture is a rapid process involving major 
changes on transcript and protein level during the first 24 hours, limiting the in vivo  
relevance of this model (study I). 
 
 In the 3D spheroid system developed here PHH are cultured under serum-free and 
defined chemical conditions. Unlike in 2D monolayer culture, PHH in 3D spheroid 
culture possess relevant hepatic phenotypes comparable to those found in the human 
liver in vivo and inter-individual variability can be retained (study II). 
 
 PHH in 3D spheroid culture remain viable, form bile canalicular networks, and have 
stable liver-specific functionalities for several weeks in culture. These features allow 
screening for drug responses and toxicity events that may be delayed in onset  
(study II). 
 
 PHH spheroids can be used to identify the liability of compounds to induce 
cholestasis and to study mechanistic aspects thereof. The PHH spheroid system may 
have additional sensitivity over PHH sandwich cultures due to the ability to assess 
chronic drug-induced cholestasis events (studies III and IV). 
  
 The propensity of drugs to induce CYP3A4 can be accurately assessed in PHH 
spheroids at clinically relevant concentrations. PHH in 3D spheroid culture, but not in 
2D monolayer culture, are able to detect an atypical mechanism of CYP3A4 induction 
of clinical importance (study V). 
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5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Unexpected adverse hepatic drug events are a significant threat to patient safety and 
negatively impact on the productivity of the pharmaceutical industry. If liver safety concerns 
are not recognized in the preclinical stage of drug development, human safety is put at risk. 
DILI is a major cause of post-marketing drug withdrawals and restricted-use warnings and is 
one of the major reasons for drug attrition during the clinical phases of development. Hence, 
it is clear that a translational gap between preclinical predictions of drug behavior and clinical 
outcomes currently exists. 
Post-marketing DILI events predominantly occur due to idiosyncratic reactions, often only 
occurring in isolated cases and several years post-marketing. Inherent to its definition, the 
nature of idiosyncratic type of drug reactions is multifaceted, requiring a complex interplay 
between various risk factors including drug properties, the environment, and genetic and non-
genetic factors of the patient. As such, it is highly unlikely that the risk for idiosyncratic liver 
injury events is recognized during drug development which in its current state merely aims to 
estimate the risk of ADR occurrence in the general population.  
A clear paradigm shift from a one-size-fits-all strategy to a new era of personalized medicine 
is ongoing where pharmacogenetic testing is slowly gaining appreciation in the clinic (323). 
In recent years, GWAS analyses have associated some common genetic variants with 
idiosyncratic DILI (e.g. certain HLA alleles). However, when used to prospectively predict 
patient-specific liver injury risks prior to drug prescription, these tests would have a high 
negative predictive value, yet a low positive predictive value due to the low incidence of 
idiosyncratic DILI (324). Instead, such tests serve more value as a diagnostic tool where liver 
injury patterns can be linked to particular drugs, thereby allowing effective continuation of 
other co-medicated drugs (325). Unless it is made possible to comprehensively assess patient-
specific drug responses in vitro using suitable patient’s material, it is unlikely that the 
majority of idiosyncratic drug reactions will be predictable prior to prescription. 
Adverse liver safety profiles during the clinical phase of drug development often appear in 
several subjects. This implies that the mechanism of hepatotoxicity is intrinsic in nature and 
thus in theory should have been predictable, highlighting the ongoing existence of a 
translational gap between preclinical liver safety prediction and clinical outcome. Animal 
models lack predictive power due to important inter-species differences, exemplified by 
various cases of unexpected toxicities in the clinic with serious injuries or fatalities as a result 
(e.g. fialuridine (189), TGN1412 (326), and BIA 10-2474 (327)). Therefore, contemporary 
research places much emphasis on developing novel human-based in vitro models to improve 
the preclinical drug toxicity testing strategies (24). 
PHH in 2D monolayer cultures have long been the preferred in vitro system to model the 
human liver. However, there is an increased recognition that in this culture format PHH 
rapidly lose their mature phenotype due to dedifferentiation (214). The results from this thesis 
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substantiate this, where we observed that PHH in 2D monolayer culture very rapidly lose the 
expression of crucial hepatic genes. Consequently, accurately predicting clinical drug 
metabolism and toxicity profiles is impeded. It is now recognized that a major reason for the 
rapid decline of hepatocyte functionality is the lack of physiological relevance of such simple 
2D culture systems. The liver in vivo has a complex 3D organization where hepatocytes are 
highly polarized which is of vital importance for proper hepatocyte functionality. 
Accordingly, various novel 3D culture platforms have been proposed to create more 
physiologically relevant in vitro liver models, ranging in complexity from sandwich cultures 
to complex microfluidic chips, each with unique advantages and shortcomings.  
To constitute a suitable model to be implemented in drug development, several characteristics 
should be considered. These include the robustness, versatility, throughput, and cost-
effectiveness of the system. In this regard, 3D spheroid cultures generated in multi-well plates 
constitute an attractive approach. In this thesis, we developed and characterized a scaffold-
free 96-well PHH spheroid system, using only 1,500 cells per well to generate a single 
spheroid of a defined size. In contrast to a previously constructed multi-liver cell type 
spheroid system where media conditions were not disclosed (263, 328), PHH spheroids in our 
system are maintained in chemically defined and serum-free conditions, thus allowing wide-
spread use of this model among researchers and industry.  
Our results indicate that the PHH spheroid system is a highly phenotypically relevant in vitro 
model, closely resembling the human liver in vivo. Importantly, we found indications that 
inter-individual variability is retained in PHH 3D spheroid culture, opening up the possibility 
to study inter-individual differences in drug response and toxicity (329). Because molecular 
phenotypes and liver-specific functions of PHH are largely stable for multiple weeks in 3D 
spheroid culture, this system is a valuable model to assess DILI events that may be delayed in 
onset. This was exemplified by the striking toxicity pattern of fialuridine that required 
prolonged exposures to exert its toxicity. Furthermore, since PHH form bile canalicular 
networks in 3D spheroid culture, the system can be used to predict and study chronic drug-
induced cholestasis. Recent reports from our lab indicate that the PHH spheroid system could 
predict DILI with 69% sensitivity and 100% specificity using a panel of 70 DILI-positive and 
53 DILI-negative compounds after two weeks of repeated exposure (330). Remarkably, the 
system outperformed other proposed DILI screening models employing PHH (235, 243), 
including also the multi-liver cell type spheroid system mentioned earlier (264), despite 
relying on lower drug concentrations (20xCmax compared to 100xCmax). The discrepancy 
between these two spheroid models might be related to differences in the choice of 
compounds, inter-donor variabilities, inclusion of NPCs, or differences in media composition. 
Furthermore, the PHH spheroid system was also recently shown to detect and reflect drug 
toxicity patterns in a more appropriate manner than other conventionally used models, 
including 2D cultures of HepaRG cells or HLCs (331), as well as PHH sandwich cultures 
(332). 
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In addition to showing promise for assessments of drug hepatotoxicity, the PHH spheroid 
system may represent a suitable platform to screen drugs for CYP3A4 induction. PHH in 3D 
spheroid culture stably express important NRs and CYPs at levels comparable to those found 
in the liver in vivo (333). Furthermore, we found that clinical CYP3A4 induction patterns 
were accurately reflected at physiologically relevant concentrations. We convincingly 
showed that 3D spheroid cultivation of PHH is necessary to identify an atypical mechanism 
leading to CYP3A4 induction. This was exemplified by the detection of AZD1208-mediated 
induction of CYP3A4 exclusively in PHH 3D spheroid culture, but not in 2D monolayer 
cultures from the same donor, indicating that activity of signaling pathways of importance for 
CYP induction are drastically altered upon cultivation of PHH as 2D monolayers. As such, 
the PHH spheroid system may constitute a promising novel preclinical model to predict 
CYP3A4 induction liabilities of drug candidates. 
While our results are encouraging and provide a step forward in establishing a more relevant 
in vitro human liver system, certain observations and limitations should be noted. We 
observed significant donor-to-donor variation of PHH fractions with regard to the ability to 
aggregate into compact spheroids, as well as differences in the long-term viability and 
stability of hepatic phenotypes. Though not specific to the chosen 3D spheroid culture 
system, this necessitates extensive initial screenings to find suitable PHH donors that perform 
well in 3D spheroid culture. Furthermore, in this thesis, we mainly focused on 3D spheroid 
cultures consisting of solely PHH. While it is true that parenchymal hepatocytes are the main 
cell type of the liver, hepatic NPCs are known to support hepatocyte function and play crucial 
roles in certain liver diseases. Our preliminary investigations suggest that spheroid co-
cultures of PHH with crude primary hepatic NPC fractions can be generated and that the 
Kupffer cells are responsive to LPS stimulation. Further characterization of the long-term 
stability of each cell type in these spheroid co-cultures is needed. It will be tremendously 
interesting to observe whether complex diseases with crucial roles for hepatic NPCs (e.g. 
NAFLD (334) and fibrosis (335)) can be reflected in such co-cultures. Indeed, 3D spheroid 
co-cultures of HepaRG cells and hepatic stellate cells were recently presented as a potential 
drug-induced fibrosis model (336). 
While the 3D spheroid culture system employed here has several features attractive for drug 
development (e.g. few cells needed for drug toxicity screenings and a higher throughput 
compared to other complex systems), perfusion is lacking and as such various physiological 
parameters cannot be controlled that could be of importance for hepatic functionality. 
Integration of PHH spheroids into microfluidic chips is therefore considered a promising 
avenue in which the microenvironment can be more tightly regulated and potential 
interactions with other organs can be generated. It is anticipated that such organotypic in vitro 
models will increase our understanding of human bodily functions, are of value for disease 
modelling and screening of novel therapeutic interventions, and may aid in enhancing safety 
assessments in drug development (337-340). 
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